Scout | Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)

This opportunity is no longer accepting applications.

grant

Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)

This grant opportunity aims to support research into how inflammasomes (protein complexes involved in immune response) affect brain health in cases of drug exposure and HIV infection. It seeks to discover how these inflammasomes are involved in virus and drug-induced immune responses, aiming to identify molecular markers and immune cells in the brain that are linked to HIV-1 in people who use …

Source

Agency: National Institutes of Health

Sub-agency: National Institute on Drug Abuse

Award

Award Ceiling: $500,000

Funding Amount: $500,000

Dates

Opportunity Released: October 29, 2024

Open for Submission: October 29, 2024

Submission Deadline: March 13, 2025

Application Window Closes: March 13, 2025

Keywords

HIV

inflammasomes

neuropathology

neuroinflammation

immune activation

substance abuse

molecular markers

CNS immune cells

drug exposure

novel therapies

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers